特发性血小板减少性紫癜免疫球蛋白和T细胞亚群等动态观察及其临床意义

目的　研究特发性血小板减少性紫癜 (ITP)患儿血清中免疫球蛋白 (Ig)和T细胞亚群及可溶性白细胞介素 2受体 (sIL - 2R)的动态变化及临床意义。方法　采用比浊法和抗体致敏红细胞花环试验等方法测定了82例ITP患儿血清Ig和T细胞亚群、sIL - 2R的变化。 结果　ITP患儿CD3 ,CD4 及其CD4 /CD8值明显低于对照组及恢复期 (P <0 .0 1) ,IgG ,IgM ,CD8明显高于对照组及恢复期 ,sIL - 2R水平较对照组明显增高 (P <0 .0 1)。治疗后随着血小板上升 ,恢复期CD3 ,CD4 ,CD4 /CD8值增高。IgG ,IgM ,CD8逐渐下降到正常水平。结论　细胞免疫和体液免疫功能参与了ITP发病过程。IgG ,IgM ,CD4 /CD8比值与疾病的预后有关。     

特发性血小板减少性紫癜T淋巴细胞亚群研究

本文对35例ITP患儿进行T淋巴细胞亚群研究，发现ITP急性期CD3、CD4明显低于正常对照，CD8与正常对照相比增高，CD4／CD8比值明显小于正常对照，显示ITP患儿存在细胞免疫紊乱，随病情好转T细胞亚群比例异常有所改善。仍未达正常水平。ITP患儿治疗后据病情恢复与否进行比较，发现恢复组与未愈组问CD4／CD8存在显著差异，提示T淋细胞亚群变化可能与ITP患儿病情恢复及疗效有关。     

干扰素治疗特发性血小板减少性紫癜患儿T细胞亚群的变化及临床意义

为探讨T细胞亚群在特发性血小板减少性紫癜(ITP)中的变化及其用干扰素(IFN)治疗的影响。采用IFN治疗ITP患儿，分别于治疗前后用SAP法检测T细胞亚群的含量。结果，ITP患儿IFN治疗前外周血CD4降低，CD8升高，CD4/CD8显著降低；IFN治疗后CD4，CD8降低，CD4，CD8明显高于治疗前。结果表明，ITP患儿T细胞亚群表达及比例失调，IFN治疗ITP有显著临床疗效。     

小儿特发性血小板减少性紫癜血小板相关抗体,T细胞亚群检测及其？…

本文对１９８９年９月至１９９５年２月收治的１１２例小儿特发性血小板减少性紫癜的血小板相关性抗体、Ｔ细胞亚群检测及其临床意义进行了探讨。结果表明：急、慢型无论是ＯＫＴ３＾＋及ＯＫＴ４＾＋均低于正常对照组，且有显著性差异，Ｐ值均〈０．０５；而ＯＫＴ８＾＋与正常对照组相比则较高，Ｐ值〈０．０２５。但是，急、慢两型相比均未见统计学上显差性差异。本文的检测血小板抗体ＩｇＧ、ＩｇＭ及ＩｇＡ，显示均有所增高尤以     

干扰素治疗特发性血小板减少性紫癜患儿T细胞亚群的变化及临床意义

为探讨T细胞亚群在特发性血小板减少性紫癜 (ITP)中的变化及其用干扰素 (IFN)治疗的影响。采用IFN治疗ITP患儿 ,分别于治疗前后用SAP法检测T细胞亚群的含量。结果 ,ITP患儿IFN治疗前外周血CD4 降低 ,CD8升高 ,CD4 CD8显著降低 ;IFN治疗后CD4 ,CD8降低 ,CD4 CD8明显高于治疗前。结果表明 ,ITP患儿T细胞亚群表达及比例失调 ,IFN治疗ITP有显著临床疗效     

特发性血小板减少性紫癜T淋巴细胞亚群和免疫球蛋白变化

目的　探讨特发性血小板减少性紫癜 (ITP)T淋巴细胞 (TC)亚群和免疫球蛋白的变化 ,为治疗提供更多方法。方法　对ITP患儿 4 0例和对照组 19例取静脉血进行TC亚群和免疫球蛋白检测。结果　观察组CD3为 (7.84± 6 .0 5 ) %明显低于对照组 (6 2 .82± 4 .88) % (P <0 .0 1) ;观察组CD4 (35 .4 2± 3.72 ) %明显低于对照组 (39.0 0± 4 .6 0 ) % (P <0 .0 1) ;观察组CD8(2 7.18± 5 .91) %高于与对照组 (2 3.5 3± 4 .5 0 ) % (P <0 .0 5 ) ;观察组CD4 /CD8(1.2 9± 0 .34)明显低于对照组 (1.5 8± 0 .12 ) (P <0 .0 1) ;观察组IgG为 (8.83± 2 .5 )g/L与对照组 (8.5 0± 3.5 ) g/L比较无明显变化 (P >0 .0 5 ) ;观察组IgA(0 .94± 0 .2 3)g/L明显高于对照组 (0 .82± 0 .2 7)g/L(P <0 .0 5 ) ;观察组IgM (0 .81± 0 .4 5 ) g/L低于对照组 (1.0 2± 0 .4 5 )g/L(P <0 .0 5 )。 结论　ITP的血小板减少与细胞和体液免疫的改变有关     

特发性血小板减少性紫癜患者血小板抗体及淋巴细胞亚群的研究

目的探讨血小板相关抗体(PAIgG)和T淋巴细胞亚群的变化,在特发性血小板减少性紫癜(ITP)免疫发病机制中的作用、临床意义。方法采用间接免疫荧光法测定30例ITP患者及20例正常对照组的PAIgG,20例ITP患儿治疗后复查PAIgG。同时采用流式细胞仪直接免疫荧光法检测外周T血淋巴细胞亚群。结果ITP组PAIgG阳性率为80%,正常对照组为20%(P<0.001),ITP组PAIgG明显高于正常对照组(P<0.001),20例ITP患儿治疗后复查PAIgG,其数值明显下降,差异有显著性(P<0.001)。T淋巴细胞亚群中,ITP组CD3、CD4、CD4/CD8显著低于正常对照组(P<0.01),CD8则显著高于正常对照组(P<0.01)。结论抗血小板相关抗体对提高ITP的诊断、疗效及预后的判断有一定的实用价值,T淋巴细胞亚群的变化能较好的反映ITP的病理机制。     

小儿特发性血小板减少性紫癜外周血T淋巴细胞观察(附41例结果分析)

本文采用免疫荧光法对41例特发性血小板减少性紫癜(ITP)患儿 T 淋巴细胞亚群及 B细胞进行了检测,观察患儿 OKT_3、OKT_4、OKT_4/OKT_8、B 细胞的比值变化,并与15例健康小儿进行了比较,发现 ITP 患儿机体免疫功能紊乱涉及到细胞及体液免疫。     

特发性血小板减少性紫癜患儿T细胞免疫功能研究

为探讨T淋巴细胞亚群和Th1/Th2相关细胞因子在儿童特发性血小板减少性紫癜 (ITP)中变化及应用肾上腺皮质激素治疗对其的影响。用PMA、Ionomycin作刺激剂 ,刺激全血中淋巴细胞表达细胞因子 ,以Mon ensin阻断细胞因子分泌至胞外 ,应用两种免疫荧光抗体同时标记淋巴细胞的膜表面特异分子和表达被阻滞在细胞内的细胞因子 ,用流式细胞仪进行检测和分析。结果 :ITP患儿外周血CD4 +细胞降低 ,CD8 +细胞升高 ,CD4 +/CD8 +降低尤为显著。治疗前Th1细胞占(20.66±2.82) %,Th2细胞占 (4.55±2.33) % ,Th1/Th2比值为4.78±0.66,明显高于正常儿童的1.43±0.19(P<0.005),治疗后与正常儿童无差异。提示ITP患儿T淋巴细胞亚群表达及比例失调 ,IFN_γ产生增多 ,TL_4产生减少 ,Th1/Th2功能异常 ;ITP是一种Th1占优势的疾病 ;肾上腺皮质激素治疗ITP能有效缓解病情     

儿童过敏性紫癜与T-细胞亚群研究

目的探讨T-细胞亚群与过敏性紫癜（HSP）及其各临床亚型的关系以明确T-细胞亚群在HSP发病机制中的作用,并通过对HSP各临床亚型患儿的血清补体系列、免疫复合物和免疫球蛋白水平进行对比分析以了解HSP各临床亚型是否在发病机制上存在差异。方法对32例未接受过糖皮质激素及其他免疫抑制治疗的初发HSP患儿用流式细胞仪检测其外周血CD3、CD4、CD8值,并与正常儿童进行对照,同时检测HSP患儿血清补体系列（C3、C4、CH50）、免疫复合物（CIC）和免疫球蛋白（IgG、IgA、IgM、IgE）。结果HSP患儿CD4及CD4／CD8值明显低于正常儿童（P均〈0．05）,而HSP各临床亚型患儿的CD3、CD4、CD8、CD4／CD8、C3、C4、CH50、CIC、IgG、IgA、IgM、IgE等水平差异无显著性。结论T细胞免疫功能紊乱与HSP发病可能存在某种联系。     

特发性血小板减少性紫癜患儿T细胞免疫功能的变化

目的 探讨Ｔ淋巴细胞亚群、白细胞介素１０（ＩＬ－１０）、γ－干扰素（ＩＦＮ－γ）在特发性血小板减少性紫癜（ＩＴＰ）中的变化及其用地塞米松（ＤＥＸ）治疗的影响。方法 采用ＤＥＸ治疗ＩＴＰ患儿,分别于治疗前后采取静脉血标本,应用改良碱性磷酸酶－抗碱性磷酸酶（ＡＰＡＡＰ）法及酶标记免疫吸附测定（ＥＬＩＳＡ）法分别检测Ｔ细胞亚群及血清ＩＬ－１０、ＩＦＮ－γ的含量。结果 ＩＴＰ患儿ＤＥＸ治疗前外周血ＣＤ４＾     

Simplified immunoglobulin treatment of idiopathic thrombocytopenic purpura

The recommended dose of intravenous IgG for idiopathic thrombocytopenic purpura has been 0.4 g/kg on 5 consecutive days. A simplified approach, giving a single infusion of 0.8-1.0 g/kg over 8 hours, has been tried in a series of 11 children with newly diagnosed disease. In 8 cases the infusion produced a prompt platelet response culminating at 128-502 X 10(9)/l after 3-13 days, and 4 of these cases required no further treatment while 2 needed a booster infusion due to an early relapse and 2 followed a chronic course. In 3 cases platelet responses were poor in spite of supplementary doses to a total of 1.4-2.0 g/kg: 2 infants failed to achieve normal platelet counts and 1 case with fulminant bleeding manifestations proved completely resistant. Significant side effects were not observed. These results indicate that IgG-therapy practically may be initiated with a single infusion, the resulting platelet response indicating the need for further infusions.     

Platelet-associated immunoglobulin G in childhood idiopathic thrombocytopenic purpura

Platelet-associated IgG was studied in children with acute and chronic ITP and in patients with thrombocytopenic SLE, using the microtiter solid-phase radioimmunoassay. Of the children with acute ITP, 85% had elevated PAIgG levels. The degree of elevation of PAIgG at onset of disease did not correlate with the development of chronicity. Of the children with acute ITP, clinically and hematologically indistinguishable from the rest, 15% had normal PAIgG values. All of 22 children with chronic ITP had elevated PAIgG values. Although there was good correlation between the platelet count and the PAIgG value in children with chronic ITP, the association was not as striking in those with acute ITP; thus, factors in addition to the level of PAIgG may contribute to the thrombocytopenia in the latter group. Patients with SLE and thrombocytopenia had higher values of PAIgG than would be predicted from the platelet count; the PAIgG value is probably not the only factor determining the degree of immune thrombocytopenia.     

Platelet-associated immunoglobulin G in childhood idiopathic thrombocytopenic purpura

Childhood ITP is an acquired hemorrhagic disorder with a heterogeneous clinical course. We measured PAIgG levels in 20 children with ITP (7 acute, 13 chronic). Both groups had significantly greater PAIgG values than age-matched normal subjects and thrombocytopenic controls (P less than 0.001). In addition, PAIgG values in chronic ITP were significantly lower than those in acute ITP (P less than 0.003). Serial PAIgG values were obtained in some patients; most returned to normal in association with clinical recovery. The measurement of PAIgG is useful in the diagnosis and follow-up of childhood ITP. PAIgG values may assist in differentiating acute and chronic disease in children.     

Anti-D immunoglobulin in the treatment of idiopathic thrombocytopenic purpura

Anti-D was evaluated in 8 RhD positive patients (6 males, 2 females) aged 2–21 years (mean 10 years) with idiopathic Thrombocytopenic Purpura (ITP). Five patients with chronic ITP and 3 patients with acute ITP were administered Anti-D in the dosage of 50 ug/kg intramuscularly (IM) for 3 consecutive days. One patient of chronic ITP received two courses of Anti-D. Patients were followed up for 7 to 16 months (mean 9 months). All three cases of acute ITP had a complete response and are in remission between 3 to 12 months of follow up. Two of five cases of chronic ITP had a partial response. Rise in platelet count was observed within 72–124 hours, and duration of response varied between 10 to 15 days. None of these patients had any significant side effects of anti-D immunoglobulin therapy. Intramuscular administration of anti-D is safe, effective and low cost alternative to IVlgG in the treatment of acute ITP.     

Suppressive effect of intravenous immunoglobulin on peripheral blood neutrophil count in patients with idiopathic thrombocytopenic purpura

PURPOSE: To determine the effect of intravenous immunoglobulin (IVIG) on neutrophil count, the authors studied patients with idiopathic thrombocytopenic purpura (ITP). PATIENTS AND METHODS: Thirty-one of 40 patients with ITP were treated with an IVIG regimen (400 mg/kg/daily for 5 days), while the other 9 were observed without any medications. Peripheral samples were examined during the clinical course. RESULTS: The absolute neutrophil count in 22 patients with no fever as a side effect decreased significantly by day 2 after the start of IVIG, but in most patients it began to increase soon after the last IVIG. There was also a significant difference between the decreased level of the absolute neutrophil count in patients with and without IVIG. However, re-administration of IVIG within 2 weeks did not significantly suppress the neutrophil count. In contrast, the neutrophil count increased in every patient with a fever as a side effect of IVIG. CONCLUSIONS: IVIG induced a decrease in peripheral blood neutrophil count in patients with ITP.